| |
| Device | DAKOCYTOMATION EGFR PHARMDX |
| Generic Name | Immunohistochemistry assay, antibody, epidermal growth factor receptor |
| Regulation Number | 864.1860 |
| Applicant | Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Carpinteria, CA 95051 |
| PMA Number | P030044 |
| Date Received | 09/29/2003 |
| Decision Date | 02/12/2004 |
| Withdrawal Date | 04/11/2024 |
| Product Code |
NQF |
| Docket Number | 04M-0433 |
| Notice Date | 09/24/2004 |
| Advisory Committee |
Pathology |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement APPROVAL FOR THE DAKOCYTOMATION EGFR PHARMDX. THE DEVICE IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLASTIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATION. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMAB). |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S001 S002 S003 S004 S005 S006 S007 |